AVITA Medical, Inc. (RCEL) Research & Development (2018 - 2026)

AVITA Medical (RCEL) has reported Research & Development for 9 consecutive years, with $13.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 5.18% year-over-year to $13.6 million; the trailing twelve-month figure through Jun 2026 stood at $51.9 million (down 11.17% YoY), and the FY2025 full-year result was $53.1 million, down 8.69% from the prior year.
• Research & Development grew to $13.6 million in Q2 2026 per RCEL's latest filing, from $11.9 million in the prior quarter.
• Across five years, Research & Development topped out at $16.3 million in Q2 2024 and bottomed at $4.8 million in Q1 2022.
• Historically, Research & Development has averaged $11.2 million across 5 years, with a median of $12.0 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Research & Development slumped 52.83% in 2022, then jumped 94.64% in 2023.
• Over 5 years, Research & Development stood at $6.3 million in 2022, then jumped by 61.08% to $10.2 million in 2023, then surged by 38.11% to $14.1 million in 2024, then dropped by 15.39% to $11.9 million in 2025, then increased by 13.7% to $13.6 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $13.6 million, $11.9 million, and $12.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.